Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
The August data brief used data from the 2017-2018 National Health Interview Survey (NHIS), looking who was more likely to ration diabetes medications as a cost-savings measure during the past 12 months.
Despite a recent shift to lower-cost options as the first line of diabetes therapy, the burden of high prescription drug costs remains a public health concern, the CDC noted. The price of insulin has been the topic of numerous hearing on Capitol Hill, and some companies have responded by introducing authorized generics or by capping prices as the wait for cheaper biosimilar insulin continues. Rationing of insulin and other supplies needed to manage diabetes is known to be a worldwide problem.
Last year, diabetes medications ranked sixth out of the top 20 therapeutic classes of dispensed prescriptions, accounting for 214 million prescriptions. In 2017, the annual per capita expense for outpatient diabetes medication was almost $5000, the CDC said.
Among adults with diagnosed diabetes, women (14.9%) were more likely than men (11.6%) not to take their medication as prescribed, although they were as likely to ask their doctor for a lower-priced medication (25.5% vs 23.4%).
The survey also found that uninsured adults aged 18 to 64 years were more likely than those with private insurance or Medicaid to not take their medication as prescribed and to ask their doctor for a lower-cost drug. Almost 36% of the uninsured did not take medication as prescribed, compared with 14% of those with private health insurance and nearly 18% of those with Medicaid coverage. Likewise, 42.6% of uninsured adults were more likely to seek out cheaper prescriptions, compared with patients who had private coverage (25.7%) or Medicaid coverage (18.8%).
Younger adults were more likely than those aged 65 and over to not take their medication as prescribed (17.9% and 7.2%, respectively) and to ask their doctor for a lower-cost drug (26.3% and 21.9%, respectively).
Among adults aged 65 and over, the percentage who did not take their diabetes medication as prescribed did not vary significantly by coverage type (private coverage, Medicare and Medicaid, Medicare Advantage, traditional fee-for-service Medicare only, other coverage, or no insurance), ranging from 6.2% for those with private insurance to 9.2% for those with traditional Medicare.
Within this group, the percentage of patients who asked their doctor for a lower-cost diabetes medication was lowest among those with Medicare and Medicaid coverage (13.0% each) compared with private (26.1%), Medicare Advantage (25.8%), or Medicare only (22.7%) coverage.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.